GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Ocado Group PLC

Unilever

London's financial calendar is a packed one next week, with BP, Ocado, GlaxoSmithKline, AstraZeneca, Unilever, British American Tobacco and Barratt among the names reporting. Although the trillion-dollar boys have had their say, don't think the US earnings season has finished either, with with a further 83 companies in the S&P 500 reporting.

BP, Ocado, GSK, Astra and Unilever make for a packed London schedule

GlaxoSmithKline is one of the eight largest pharmaceutical companies in the world. The company's revenue continues to grow QoQ with a 9.3% increase in Q3 2021 compared to Q2 2021. Vaccine sales were £2,174 million in Q3 2021, up 38.4% from Q2.

GlaxoSmithKline: 4.57% Dividend Yield And Cure For COVID-19 And HIV

Gilead Sciences

GlaxoSmithKline plc GSK has settled a patent dispute between ViiV Healthcare and Gilead Sciences Inc GILD. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead

GlaxoSmithKline PLC (LSE:GSK) has confirmed that an HIV drug business it majority-owns has agreed a US$1.25bn settlement with competitor Gilead Sciences. ViiV, a joint venture between GSK, Pfizer and Japan's Shionogi, claimed Gilead's triple combination treatment Biktarvy infringed the JV's patents over an existing drug, dolutegravir.

GlaxoSmithKline JV to receive US$1.25bn after HIV case settlement

GlaxoSmithKline PLC announced a settlement worth $1.25 billion between its ViiV Healthcare and Gilead Sciences Inc on Tuesday in relation to patent violations by Gilead's Biktarvy, a medicine to treat human immunodeficiency virus.

GSK announces $1.25 billion settlement between ViiV Healthcare, Gilead

Pfizer

The FDA has approved ViiV Healthcare's Apretude (cabotegravir extended-release injectable suspension) for use in adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV.  Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

FDA Approves First Injectable For HIV Pre-Exposure Prevention - GSK, Pfizer Backed Treatment

In the latest trading session, GlaxoSmithKline (GSK) closed at $45.25, marking a -1.07% move from the previous day.

GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know

A spinoff still seems to be the best alternative for GlaxoSmithKline.

Should GlaxoSmithKline Have Accepted Unilever's $68 Billion Consumer Health Offer?

Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.

Glaxo's (GSK) New Drugs Drive Sales Amid Rising Competition

In the latest trading session, GlaxoSmithKline (GSK) closed at $45.10, marking a +0.49% move from the previous day.

GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know

Vir Biotechnology

GlaxoSmithKline and U.S. partner Vir Biotechnology will boost production of their antibody-based COVID-19 treatment by adding a second manufacturing plant to help meet soaring demand in the United States.

GSK, Vir ramping up U.S. output of COVID antibody drug

Unilever PLC ( UL , Financial) said on Wednesday that it will not raise its already rejected bid of 50 billion pounds ($68 billion) for GlaxoSmithKline PLC's ( GSK , Financial) consumer health care business – and investors aren't happy.

Unilever Stands Pat on GlaxoSmithKline Decision

Unilever decides that it will not raise its offer of $68 billion for Glaxo's (GSK) Consumer Healthcare business.

Glaxo (GSK) Stock Down As Unilever Decides Not to Raise Offer

Influential British fund manager Terry Smith attacked Unilever's failed 50 billion pound ($68.2 billion) bid for GSK's Consumer Health assets as a "near death experience" and urged Unilever management to focus on strengthening performance.

Shareholder Terry Smith labels Unilever's GSK bid "near death experience"

Shares in Unilever inched roughly 2% higher on Thursday after the consumer goods giant said it would not raise its rejected £50 billion ($68 billion) offer for GlaxoSmithKline's consumer health care business.

Unilever ends pursuit of GSK's consumer health business

Shares in Unilever PLC (LSE:ULVR) rose and GlaxoSmithKline PLC (LSE:GSK) fell after the Anglo-Dutch group said late yesterday it was abandoning its pursuit of the GSK Consumer Healthcare joint venture after criticism from investors. Consumer goods giant Unilever said as the markets closed it will not increase its offer above £50bn after the joint venture's owners GSK and Pfizer Inc (NYSE:PFE) argued the business was worth more.

Unilever drops bid for GSK Consumer Healthcare venture

Shares in consumer goods giant Unilever inched roughly 2% higher on Thursday after it said late on Wednesday it would not raise its rejected 50 billion pound ($68 billion) offer for GlaxoSmithKline's consumer healthcare business.

Unilever shares gain after opting not to lift bid for GSK assets

Unilever PLC (LSE:ULVR) has abandoned its pursuit of the Consumer Healthcare joint venture owned by GlaxoSmithKline PLC (LSE:GSK) and Pfizer Inc (NYSE:PFE) after criticism from investors. The Anglo-Dutch consumer goods giant said late yesterday that it will not increase its offer above £50bn after GSK and Pfizer said they felt the business was worth more.

Unilever drops bid for GSK Consumer Healthcare

Unilever made a third bid of £50 billion for GlaxoSmithKline's (GSK) consumer health business in December. GSK rejected the bid and still plans on spinning off the CH business under its own listing mid-2022.

GlaxoSmithKline Rejects Offer For Their Consumer Health Unit

(Reuters) -Dove soap maker Unilever PLC said on Wednesday it would not increase its 50-billion-pound ($68 billion) proposal to buy GSK's consumer healthcare business.

Unilever will not increase 50-billion-pound offer for GSK consumer arm

GlaxoSmithKline PLC (LSE:GSK) said it appointed Tony Wood as chief scientific officer designate to replace current CSO Hal Barron. Wood will take over from Barron on 1 August 2022 and assume full accountability for Research and Development (R&D), the pharmaceutical company said in a statement.

GlaxoSmithKline names Tony Wood chief scientific officer to succeed Hal Barron

Johnson & Johnson

GlaxoSmithKline PLC ( GSK , Financial), Pfizer Inc. ( PFE , Financial) and Johnson & Johnson ( JNJ , Financial) should all know about mid-year if the shots they're developing for a common and potentially fatal virus is effective. No, the it isn't for Covid-19, but for respiratory syncytial virus, which causes an estimated 177,000 hospitalizations among older adults each year and 58,000 in children under five.

Pharma Giants Go After $10 Billion Market With RSV Drugs

The Unilever bid for certain Glaxo assets produces a classic example of a standard arbitrage technique. Most takeovers and purchases lose money for the acquiring shareholders and make for the acquired.

Unilever And Glaxo - A Classic Arbitrage Example

Novartis

Surface Oncology Inc

SURF is an early-stage cancer therapeutics company with multiple big pharma partnerships.

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Shares of Unilever plc (LON: ULVR) slid 4.0% on Monday after the British multinational said it was still interested in buying GlaxoSmithKline plc's (LON: GSK) consumer business. GSK continues to reject Unilever's proposals So far, GSK has rejected three of Unilever's proposals, including the most recent one that was valued at $68.25 billion.

News for GlaxoSmithKline Stock (GSK)